Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease

Trial Profile

A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs Ustekinumab (Primary) ; Ustekinumab (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole; Warfarin
  • Indications Crohn's disease
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 21 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 02 Feb 2018 Planned initiation date changed from 8 Jan 2018 to 2 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top